Dr. Cicchetti obtained her Ph.D. in neurobiology from Laval University in Québec City (Canada) in 1998. In 2002, she completed a postdoctoral fellowship at Harvard Medical School in the field of cell replacement therapy for neurodegenerative disorders. She is now a professor for the department of Psychiatry & Neurosciences, of Laval University’s Medical School in Québec City. Dr. Cicchetti has published over 80 manuscripts in various high impact journals such as PNAS, Annals of Neurology, Acta Neuropathologica, Trends in Pharmacology, and Brain. She has received numerous awards and distinctions, including the Canadian Institutes of Health Research New Investigator Award (2007-2012), the Fonds de Recherche en Santé du Québec (FRSQ) Junior Research Award (2003-2006 and 2006-2007), Young Investigator Award from NARSAD (2006) and Parkinson Society Canada (2002) and more recently, the prestigious National Researcher award from FRQS (2014-2017), followed by an FRQS research Chair (2017-2021). Three of her recent publications (2014, 2015, 2016) have been awarded most influential papers in the field of Huntington’s disease. She is an active member of several scientific committees and editorial boards.

Our research program is built on 3 distinct themes: 1) to better understand the phenomena that may contribute to the development or the propagation of the pathological aspects found in neurodegenerative diseases (in particular Parkinson’s and Huntington’s) and related-cognitive features; 2) to develop therapeutic strategies that would allow an early or late intervention in the evolution of the disease; 3) to study the mechanisms of action underlying the beneficial and/or detrimental effects of current experimental therapies (cell transplantation and deep brain stimulation) in order to improve these methodologies for the clinic. Our research program is based on translational research, from the animal model to the clinic, with the goal of developing novel therapeutic targets for individuals suffering from Parkinson’s and/or Huntington’s diseases. With this research program, we have developed a considerable expertise in the animal models of these diseases, in imaging/microscopy in small animals, but more importantly in the histopathological analyses of human tissue. Our collaborations with various clinicians provide us invaluable access to human samples (blood, spinal cord, and brain), at times extremely rare (ex.: the brains of transplanted patients). Various pharmaceutical/industrial partners with whom we also collaborate will help us accelerate our findings to tangible clinical applications.

CHUL
2705, boulevard Laurier
T2-07
Québec, Québec
Canada G1V 4G2
104 entries « 11 of 11 »

Parent A, Cicchetti F

[Anatomy and physiopathology of the basal ganglia]

Journal Article

Neurochirurgie, 43 Suppl 1 , pp. 33-40, 1997, ISSN: 0028-3770.

| Links:

Cicchetti F, Parent A

Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons.

Journal Article

Mov Disord, 11 (6), pp. 619-26, 1996, ISSN: 0885-3185.

Abstract | Links:

Cicchetti F, Gould PV, Parent A

Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease.

Journal Article

Brain Res, 730 (1-2), pp. 232-7, 1996, ISSN: 0006-8993.

Abstract | Links:

Parent A, Fortin M, Côté PY, Cicchetti F

Calcium-binding proteins in primate basal ganglia.

Journal Article

Neurosci Res, 25 (4), pp. 309-34, 1996, ISSN: 0168-0102.

Abstract | Links:

104 entries « 11 of 11 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2023-05-01
  • Compréhension de la pathogénèse des maladies neurodégénératives et développement de stratégies thérapeutiques, Subvention, Fonds de recherche du Québec - Santé, Chaires de recherche FRQS, from 2017-07-01 to 2021-06-30
  • CRISPR-Cas9 nickase as a new approach to treat Huntington’s disease, Subvention, Société Huntington du Canada, from 2019-07-01 to 2021-06-30
  • Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2020-04-01 to 2025-03-31
  • Untangling tau contribution to cognitive impairments in Huntington’s disease., Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-04-01 to 2024-03-31

Recently finished projects

  • Mutant protein spread in Huntington's disease and its implications for other neurodegenerative disorders of the CNS., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
  • Projet de recherche clinique sur la maladie de Parkinson (Cystamine), Subvention, Fondation du CHU de Québec, from 2019-04-01 to 2020-03-31
Data provided by the Université Laval research projects registery